Breaking News Instant updates and real-time market news.

AKBA

Akebia

$6.93

-0.22 (-3.08%)

, FGEN

FibroGen

$46.14

-2.31 (-4.77%)

09:25
04/18/19
04/18
09:25
04/18/19
09:25

Piper Jaffray biotech analysts to hold an analyst/industry conference call

Biotech Analysts Brill and Raymond, along with a Key Opinion Leader who is an expert in renal disease, will discuss HIF-stabilizers, the upcoming major adverse cardiac events (MACE) analyses with Fibrogen's roxadustat and Akebia's vadadustat on an Analyst/Industry conference call to be held on April 18 at 10 am.

AKBA

Akebia

$6.93

-0.22 (-3.08%)

FGEN

FibroGen

$46.14

-2.31 (-4.77%)

  • 18

    Apr

  • 22

    Apr

  • 06

    May

AKBA Akebia
$6.93

-0.22 (-3.08%)

04/03/19
HCWC
04/03/19
NO CHANGE
Target $23
HCWC
Buy
Akebia should be bought on yesterday's weakness, says H.C. Wainwright
Akebia Therapeutics shares dropped 13% yesterday due to investor concerns about the mention of the phrase "Hy's Law'" related to a subject from a prior Phase 2b study of vadadustat in last week's annual filing, H.C. Wainwright analyst Ed Arce tells investors in a research note. The subject met the first two criteria for the law, but not the third, as investigators were unable to rule out other potential causes of injury, adds the analyst. He finds it important that the subject made a complete recovery after both vadadustat and chlorthalidone were discontinued. Further, "there is nothing new here in terms of data," says Arce. He believes nothing fundamentally has changed from the disclosure and would be a buyer of Akebia on yesterday's weakness. The analyst raised his price target for the stock to $23 from $22 after adding Auryxia to his model and keeps a Buy rating on the name.
04/03/19
MZHO
04/03/19
NO CHANGE
Target $16
MZHO
Buy
Akebia selloff on vadadustat disclosure a buying opportunity, says Mizuho
Mizuho analyst Difei Yang attributes the recent weakness in shares of Akebia Therapeutics to a disclosure on the Phase 2b study of vadadustat in its latest annual report that reads: "One subject with multiple co-morbidities and concomitant medications, including chlorthalidone, had an SAE of liver function test, or LFT, abnormal, considered a case of drug-induced liver injury meeting the biochemical criteria of Hy's Law, which was assessed as probably related to vadadustat." The new key piece of info here relates to the linkage of this serious adverse event to Hy's Law, Yang tells investors in a research note. However, out of the three components of Hy's Law cases, Akebia management confirmed that the patient in question from the Phase 2b study met the first two criteria, but not the third, says the analyst. Further, in that same Phase 2b study, three patient deaths occurred in the vadadustat treatment arm, none of which have been linked with Hy's Law, Yang adds. In addition, this is not completely new news, she says after speaking to management. Yang recommends buying shares of Akebia following the recent weakness. She keeps a Buy rating on the name with a $16 price target.
04/02/19
RAJA
04/02/19
NO CHANGE
RAJA
Akebia selloff on 'stale' safety concern an overreaction, says Raymond James
Raymond James analyst Reni Benjamin attributes the selloff today in shares of Akebia Therapeutics to "stale" vadadustat safety concerns. After speaking with management the analyst views the selloff as an overreaction.
03/20/19
SBSH
03/20/19
INITIATION
Target $9
SBSH
Neutral
Citi starts Akebia Therapeutics with Neutral, $9 price target
Citi analyst Yigal Nochomovitz started Akebia Therapeutics with a Neutral rating and $9 price target. The re-launch of Auryxia in Q4 by Keryx exceeded expectations and the drug should continue to gain steady additional market share, Nochomovitz tells investors in a research note. However, while he expects Auryxia net revenues will continue to increase year-over-year through 2024, the analyst sees a steady decline in the year-over-year growth rate.
FGEN FibroGen
$46.14

-2.31 (-4.77%)

04/12/19
PIPR
04/12/19
INITIATION
Target $65
PIPR
Neutral
FibroGen initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Danielle Brill started FibroGen with a Neutral rating and $65 price target. The analyst thinks roxadustat will show non-inferiority to erythropoiesis-stimulating agents in dialysis-dependent chronic kidney disease but her level of conviction is low. She believes risk is skewed to the downside and is not a buyer of the shares into the major adverse cardiovascular events data.
02/28/19
JEFF
02/28/19
NO CHANGE
Target $75
JEFF
Buy
FibroGen upcoming Phase 3 data could drive 'significant rally,' says Jefferies
Jefferies analyst Michael Yee likes FibroGen shares for the upcoming Phase III roxadustat anemia MACE data by the first half of 2019. He deems the readout a "significant de-risking event." There's a lot of uncertainty on any safety imbalances so if data is indeed non-inferior on MACE, "there could be a significant rally and re-rating on the stock," Yee tells investors in a research note. He believes roxadustat "is a safe drug that has already shown very positive and statistically-superior efficacy." The analyst keeps a Buy rating on FibroGen with a $75 price target.
02/11/19
STFL
02/11/19
INITIATION
Target $71
STFL
Buy
FibroGen resumed with a Buy at Stifel
Stifel analyst Adam Walsh resumed coverage of FibroGen with a Buy rating and $71 price target. The analyst likes the share setup into the roxadustat MACE safety data in CKD anemia. These results should help clarify for investors the ultimate commercial opportunity for the drug, Walsh tells investors in a research note. His "base-case outcome scenario" for the MACE data, an estimated 70% probability of success, points to $16 upside from current share levels.
01/29/19
MZHO
01/29/19
NO CHANGE
Target $74
MZHO
Buy
FibroGen shares have 'significant upside' on positive data, says Mizuho
Following positive efficacy results from roxadustat in December, investor attention remains focused on the upcoming MACE safety data expected around April, Mizuho analyst Difei Yang tells investors in a research note. The analyst sees "strong potential" in roxadustat and believes the drug could be a safer alternative to erythropoiesis-stimulating agents. Yang's base case scenario has $21 per share of upside on the data readout versus $8 per share downside in her bear case scenario. She sees "significant upside" if the data are positive and reiterates a Buy rating on FibroGen with a $74 price target.

TODAY'S FREE FLY STORIES

03:30
04/25/19
04/25
03:30
04/25/19
03:30
General news
FX Action: USD-CAD rallied for a second day »

FX Action: USD-CAD…

02:50
04/25/19
04/25
02:50
04/25/19
02:50
General news
BoJ ready to adjust policy if needed. »

BoJ ready to adjust…

02:35
04/25/19
04/25
02:35
04/25/19
02:35
General news
FX Update: The dollar has consolidated »

FX Update: The dollar has…

02:10
04/25/19
04/25
02:10
04/25/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

MTSI

Macom

$15.86

-0.33 (-2.04%)

21:33
04/24/19
04/24
21:33
04/24/19
21:33
Downgrade
Macom rating change at Evercore ISI »

Macom downgraded to In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

GRTS

Gritstone Oncology

$12.32

-0.63 (-4.86%)

20:58
04/24/19
04/24
20:58
04/24/19
20:58
Syndicate
Gritstone Oncology 6.5M share Secondary priced at $11.50 »

Goldman Sachs, Cowen,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MTSI

Macom

$15.86

-0.33 (-2.04%)

20:56
04/24/19
04/24
20:56
04/24/19
20:56
Downgrade
Macom rating change at Jefferies »

Macom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

CBS

CBS

$51.34

-0.01 (-0.02%)

, VIAB

Viacom

$29.69

0.42 (1.43%)

20:39
04/24/19
04/24
20:39
04/24/19
20:39
Periodicals
CBS board has restarted talks about a bid for Viacom, NBC reports »

The board members of CBS…

CBS

CBS

$51.34

-0.01 (-0.02%)

VIAB

Viacom

$29.69

0.42 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 14

    May

INTC

Intel

$58.72

-0.06 (-0.10%)

20:34
04/24/19
04/24
20:34
04/24/19
20:34
Periodicals
Intel lays off dozens in autonomous vehicle division, The Information reports »

Several dozen workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 16

    May

  • 03

    Jun

CMCSA

Comcast

$41.87

-0.11 (-0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

20:25
04/24/19
04/24
20:25
04/24/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CMCSA

Comcast

$41.87

-0.11 (-0.26%)

CMCSK

Comcast

$0.00

(0.00%)

MMM

3M

$219.24

-0.28 (-0.13%)

ABBV

AbbVie

$78.71

0.06 (0.08%)

MO

Altria Group

$54.70

-0.14 (-0.26%)

UPS

UPS

$114.39

0.79 (0.70%)

BMY

Bristol-Myers

$44.63

-0.69 (-1.52%)

RTN

Raytheon

$185.44

-2.08 (-1.11%)

ITW

Illinois Tool Works

$156.78

-1.14 (-0.72%)

BAX

Baxter

$76.31

-0.02 (-0.03%)

VLO

Valero

$87.75

-2.53 (-2.80%)

LUV

Southwest

$52.92

0.11 (0.21%)

HSY

Hershey

$117.01

0.16 (0.14%)

ROK

Rockwell Automation

$188.97

-0.405 (-0.21%)

HES

Hess Corp.

$65.79

-1.67 (-2.48%)

FCX

Freeport McMoRan

$13.57

0.115 (0.85%)

IP

International Paper

$44.30

-0.37 (-0.83%)

DHI

D.R. Horton

$46.67

0.275 (0.59%)

TSCO

Tractor Supply

$104.09

0.88 (0.85%)

MAS

Masco

$39.98

-0.02 (-0.05%)

IVZ

Invesco

$21.53

-0.09 (-0.42%)

CLF

Cleveland-Cliffs

$9.52

0.025 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

  • 28

    Apr

  • 30

    Apr

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 06

    May

  • 06

    May

  • 07

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 13

    May

  • 14

    May

  • 15

    May

  • 15

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 13

    Nov

PBR

Petrobras

$15.34

-0.45 (-2.85%)

20:15
04/24/19
04/24
20:15
04/24/19
20:15
Periodicals
Breaking Periodicals news story on Petrobras »

Petrobras to dismiss…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTI

British American Tobacco

$39.33

-0.45 (-1.13%)

19:28
04/24/19
04/24
19:28
04/24/19
19:28
Periodicals
BAT faces legal action over giving workers free cigarettes, Bloomberg says »

Lawyers are weighing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POR

Portland General Electric

$51.20

0.61 (1.21%)

19:22
04/24/19
04/24
19:22
04/24/19
19:22
Hot Stocks
Portland General Electric raises quarterly dividend 6.3% to 38.5c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

WPG

Washington Prime

$4.55

-0.08 (-1.73%)

19:14
04/24/19
04/24
19:14
04/24/19
19:14
Earnings
Washington Prime reports Q1 FFO 31c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 16

    May

  • 16

    May

  • 04

    Jun

AVH

Avianca

$3.91

-0.09 (-2.25%)

19:14
04/24/19
04/24
19:14
04/24/19
19:14
Hot Stocks
Avianca CEO Rincon to retire effective April 30 »

Avianca Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAM

Boston Beer

$276.71

-1.24 (-0.45%)

, AXTI

AXT Inc.

$4.74

0.09 (1.94%)

19:03
04/24/19
04/24
19:03
04/24/19
19:03
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SAM

Boston Beer

$276.71

-1.24 (-0.45%)

AXTI

AXT Inc.

$4.74

0.09 (1.94%)

FBHS

Fortune Brands

$49.89

0.53 (1.07%)

BCOV

Brightcove

$8.72

0.12 (1.40%)

FB

Facebook

$182.64

-1.13 (-0.61%)

NOW

ServiceNow

$242.41

-1.085 (-0.45%)

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

LRCX

Lam Research

$195.40

0.56 (0.29%)

TILE

Interface

$17.11

0.22 (1.30%)

CHDN

Churchill Downs

$92.16

2.66 (2.97%)

KN

Knowles

$18.48

0.05 (0.27%)

CMG

Chipotle

$710.00

7.61 (1.08%)

TSLA

Tesla

$258.70

-5.15 (-1.95%)

XLNX

Xilinx

$139.79

2.66 (1.94%)

PTC

PTC

$101.94

1.12 (1.11%)

NTGR

Netgear

$35.03

-0.18 (-0.51%)

SAVE

Spirit Airlines

$58.30

0.82 (1.43%)

ORLY

O'Reilly Automotive

$396.80

1.14 (0.29%)

MMLP

Martin Midstream Partners

$9.84

-0.285 (-2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 28

    Apr

  • 01

    May

  • 05

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 13

    May

  • 14

    May

  • 14

    May

  • 16

    May

  • 21

    May

  • 21

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 12

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

PBFX

PBF Logistics

$21.36

-0.37 (-1.70%)

, PBF

PBF Energy

$33.09

-0.805 (-2.38%)

19:02
04/24/19
04/24
19:02
04/24/19
19:02
Earnings
PBF Logistics reports preliminary Q1 revenue $78.3M-$79.3M, consensus $78.17M »

Reports preliminary Q1…

PBFX

PBF Logistics

$21.36

-0.37 (-1.70%)

PBF

PBF Energy

$33.09

-0.805 (-2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 23

    May

PBFX

PBF Logistics

$21.36

-0.37 (-1.70%)

, PBF

PBF Energy

$33.09

-0.805 (-2.38%)

19:01
04/24/19
04/24
19:01
04/24/19
19:01
Hot Stocks
PBF Logistics acquires remaining 50% interest in Torrance Valley Pipeline Compan »

PBF Logistics (PBFX)…

PBFX

PBF Logistics

$21.36

-0.37 (-1.70%)

PBF

PBF Energy

$33.09

-0.805 (-2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 23

    May

NOW

ServiceNow

$242.41

-1.085 (-0.45%)

18:58
04/24/19
04/24
18:58
04/24/19
18:58
Hot Stocks
ServiceNow CEO: We are the IT system of record »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 05

    May

PBFX

PBF Logistics

$21.36

-0.37 (-1.70%)

18:57
04/24/19
04/24
18:57
04/24/19
18:57
Syndicate
PBF Logistics announces registered direct offering of 6.59M common units »

PBF Logistics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

NFBK

Northfield Bancorp

$14.70

0.09 (0.62%)

18:56
04/24/19
04/24
18:56
04/24/19
18:56
Hot Stocks
Northfield Bancorp raises quarterly dividend to 11c from 10c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    May

  • 22

    May

NFBK

Northfield Bancorp

$14.70

0.09 (0.62%)

18:55
04/24/19
04/24
18:55
04/24/19
18:55
Earnings
Northfield Bancorp reports Q1 EPS 19c, consensus 19c »

Reports Q1 NII $27.3M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    May

  • 22

    May

ZUO

Zuora

$20.03

0.04 (0.20%)

18:42
04/24/19
04/24
18:42
04/24/19
18:42
Hot Stocks
Zuora CEO: Subscription based business models are on the rise »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jun

TSLA

Tesla

$258.70

-5.15 (-1.95%)

, MXWL

Maxwell

$4.28

-0.095 (-2.17%)

18:31
04/24/19
04/24
18:31
04/24/19
18:31
Hot Stocks
Tesla says 50% of deliveries occurred in last 10 days of quarter »

Says: Overseas volume…

TSLA

Tesla

$258.70

-5.15 (-1.95%)

MXWL

Maxwell

$4.28

-0.095 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

OMAB

OMA Airports

$48.34

-0.25 (-0.51%)

18:18
04/24/19
04/24
18:18
04/24/19
18:18
Earnings
OMA Airports reports Q1 EPS 67c, two estimates 73c »

Reports Q1 traffic up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.